Adlai Nortye Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
9.95
-0.21 (-2.12%)
At close: Jun 26, 2026, 4:00 PM EDT
10.00
+0.05 (0.55%)
After-hours: Jun 26, 2026, 4:00 PM EDT
Adlai Nortye Earnings Call Transcripts
Fiscal Year 2026
-
Two RAS-targeted programs are advancing, with AN9025 in phase I and AN4035 ADC entering clinical studies in 2024. Intermittent dosing may widen the therapeutic window, and the ADC platform enables selective tumor targeting and rational combinations, especially in colorectal cancer.